Athena Countouriotis and her team at Avenzo Therapeutics have reeled in an additional $150 million just two and a half months after in-licensing their first clinical-stage asset. With the Series A-1, the biotech has now raised $347 million in total financing since its August 2022 inception, Avenzo told Endpoints News Tuesday morning. That makes it … Continue reading Athena Countouriotis’ Avenzo nabs $150M to in-license more assets